Trade G1 Therapeutics - GTHX CFD

Add to favourite

4.06

1.21%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.05

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

G1 Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	4.14
Open*	4.12
1-Year Change*	48.2%
Day's Range*	4.08 - 4.28
52 wk Range	1.08-8.40
Average Volume (10 days)	1.35M
Average Volume (3 months)	27.60M
Market Cap	183.53M
P/E Ratio	-100.00K
Shares Outstanding	51.84M
Revenue	77.89M
EPS	-1.47
Dividend (Yield %)	N/A
Beta	1.72
Next Earnings Date	Feb 28, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	4.14	-0.11	-2.59%	4.25	4.25	4.01
Apr 17, 2024	4.25	0.27	6.78%	3.98	4.33	3.97
Apr 16, 2024	4.05	-0.12	-2.88%	4.17	4.29	3.97
Apr 15, 2024	4.28	-0.26	-5.73%	4.54	4.54	4.16
Apr 12, 2024	4.50	-0.10	-2.17%	4.60	4.67	4.37
Apr 11, 2024	4.65	0.08	1.75%	4.57	4.77	4.52
Apr 10, 2024	4.62	0.03	0.65%	4.59	4.66	4.39
Apr 9, 2024	4.85	0.16	3.41%	4.69	4.87	4.63
Apr 8, 2024	4.74	0.05	1.07%	4.69	4.82	4.30
Apr 5, 2024	4.75	0.21	4.63%	4.54	4.80	4.44
Apr 4, 2024	4.53	-0.21	-4.43%	4.74	4.80	4.43
Apr 3, 2024	4.69	0.19	4.22%	4.50	4.80	4.47
Apr 2, 2024	4.57	0.12	2.70%	4.45	4.65	4.35
Apr 1, 2024	4.52	0.26	6.10%	4.26	4.61	4.10
Mar 28, 2024	4.29	-0.19	-4.24%	4.48	4.64	4.28
Mar 27, 2024	4.46	0.16	3.72%	4.30	4.73	4.25
Mar 26, 2024	4.28	0.12	2.88%	4.16	4.36	4.10
Mar 25, 2024	4.10	0.18	4.59%	3.92	4.32	3.92
Mar 22, 2024	3.97	0.29	7.88%	3.68	4.06	3.61
Mar 21, 2024	3.67	0.24	7.00%	3.43	3.71	3.42

G1 Therapeutics Events

Time (UTC)	Country	Event
Wednesday, May 1, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 G1 Therapeutics Inc Earnings Release Q1 2024 G1 Therapeutics Inc Earnings Release Forecast - Previous -
Friday, June 14, 2024
Time (UTC) 11:30	Country US	Event G1 Therapeutics Inc Annual Shareholders Meeting G1 Therapeutics Inc Annual Shareholders Meeting Forecast - Previous -
Wednesday, July 31, 2024
Time (UTC) 12:30	Country US	Event Q2 2024 G1 Therapeutics Inc Earnings Release Q2 2024 G1 Therapeutics Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	51.301	31.476	45.285	0	0
Revenue	51.301	31.476	45.285	0	0
Total Operating Expense	187.479	173.733	141.761	129.041	89.286
Selling/General/Admin. Expenses, Total	101.033	96.491	69.445	40.648	18.603
Research & Development	82.698	75.426	72.316	88.393	70.683
Operating Income	-136.178	-142.257	-96.476	-129.041	-89.286
Other, Net	0.003	-0.546	-0.542	6.594	3.998
Net Income Before Taxes	-145.859	-147.427	-97.844	-122.447	-85.288
Net Income After Taxes	-147.559	-148.352	-99.254	-122.447	-85.288
Net Income Before Extra. Items	-147.559	-148.352	-99.254	-122.447	-85.288
Net Income	-147.559	-148.352	-99.254	-122.447	-85.288
Total Adjustments to Net Income	0			0	0
Income Available to Common Excl. Extra. Items	-147.559	-148.352	-99.254	-122.447	-85.288
Income Available to Common Incl. Extra. Items	-147.559	-148.352	-99.254	-122.447	-85.288
Dilution Adjustment
Diluted Net Income	-147.559	-148.352	-99.254	-122.447	-85.288
Diluted Weighted Average Shares	43.6261	41.9434	37.878	37.4993	33.3167
Diluted EPS Excluding Extraordinary Items	-3.38235	-3.53696	-2.62036	-3.26532	-2.55992
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS	-3.38235	-3.54005	-2.62036	-3.26532	-2.55992
Interest Income (Expense), Net Non-Operating	-9.684	-4.624	-0.826
Cost of Revenue, Total	3.748	2.016
Gross Profit	47.553	29.46
Unusual Expense (Income)		-0.2

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	42.392	12.946	10.25	23.576	10.573
Revenue	42.392	12.946	10.25	23.576	10.573
Cost of Revenue, Total	1.404	1.459	0.992	1.111	0.976
Gross Profit	40.988	11.487	9.258	22.465	9.597
Total Operating Expense	30.876	38.692	41.137	45.124	47.535
Selling/General/Admin. Expenses, Total	17.432	21.753	23.558	24.432	25.716
Research & Development	12.04	15.48	16.587	19.581	20.843
Operating Income	11.516	-25.746	-30.887	-21.548	-36.962
Interest Income (Expense), Net Non-Operating	-2.067	-2.373	-2.518	-2.553	-2.357
Other, Net	0.569	0.524	0.237	0.048	-0.127
Net Income Before Taxes	10.018	-27.595	-33.168	-24.053	-39.446
Net Income After Taxes	8.71	-27.595	-33.649	-25.272	-39.446
Net Income Before Extra. Items	8.71	-27.595	-33.649	-25.272	-39.446
Net Income	8.71	-27.595	-33.649	-25.272	-39.446
Income Available to Common Excl. Extra. Items	8.71	-27.595	-33.649	-25.272	-39.446
Income Available to Common Incl. Extra. Items	8.71	-27.595	-33.649	-25.272	-39.446
Diluted Net Income	8.71	-27.595	-33.649	-25.272	-39.446
Diluted Weighted Average Shares	61.0405	51.6479	46.309	42.7993	42.7077
Diluted EPS Excluding Extraordinary Items	0.14269	-0.53429	-0.72662	-0.59048	-0.92363
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	0.14269	-0.53429	-0.72662	-0.59048	-0.92363

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	179.5	243.565	216.392	271.003	370.133
Cash and Short Term Investments	145.07	221.186	207.306	269.208	369.29
Cash & Equivalents	94.594	221.186	207.306	269.208	369.29
Prepaid Expenses	7.094	13.157	8.786	1.732	0.843
Total Assets	187.965	254.094	228.552	284.831	371.27
Property/Plant/Equipment, Total - Net	7.951	9.048	10.508	13.391	1.137
Property/Plant/Equipment, Total - Gross	9.777	10.344	11.335	14.068	1.459
Accumulated Depreciation, Total	-1.826	-1.296	-0.827	-0.677	-0.322
Total Current Liabilities	35.588	27.613	23.443	19.769	12.362
Accounts Payable	7.431	2.897	3.572	3.684	3.377
Accrued Expenses	26.692	24.295	17.474	16.085	8.985
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	1.465	0.421	2.397
Total Liabilities	119.218	110.553	51.201	29.304	12.45
Total Long Term Debt	77.015	75.19	19.893	0	0
Total Equity	68.747	143.541	177.351	255.527	358.82
Redeemable Preferred Stock
Common Stock	0.005	0.004	0.004	0.004	0.004
Retained Earnings (Accumulated Deficit)	-732.018	-584.459	-436.107	-336.853	-214.406
Treasury Stock - Common	-0.008	-0.008	-0.008	-0.008	-0.008
Total Liabilities & Shareholders’ Equity	187.965	254.094	228.552	284.831	371.27
Total Common Shares Outstanding	51.4994	42.5621	38.1141	37.6116	37.2421
Other Liabilities, Total	6.615	7.75	7.865	9.535	0.088
Additional Paid-In Capital	800.768	728.004	613.462	592.384	573.23
Other Current Assets, Total	0.063	0.063	0.063	0.063
Other Long Term Assets, Total	0.514	1.481	1.652	0.437
Total Receivables, Net	11.094	5.688	0.237
Accounts Receivable - Trade, Net	11.094	5.688	0.237
Long Term Debt	77.015	75.19	19.893
Total Inventory	16.179	3.471
Short Term Investments	50.476

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	126.103	140.436	153.965	179.5	157.465
Cash and Short Term Investments	94.352	104.231	116.317	145.07	122.982
Cash & Equivalents	52.623	55.914	68.237	94.594	93.238
Total Receivables, Net	9.265	13.171	16.025	11.094	10.521
Accounts Receivable - Trade, Net	9.265	13.171	16.025	11.094	10.521
Total Inventory	13.491	15.6	15.543	16.179	13.95
Prepaid Expenses	8.932	7.371	6.017	7.094	9.949
Other Current Assets, Total	0.063	0.063	0.063	0.063	0.063
Total Assets	133.097	147.891	161.957	187.965	166.573
Property/Plant/Equipment, Total - Net	6.78	7.173	7.564	7.951	8.365
Property/Plant/Equipment, Total - Gross	8.995	9.261	9.522	9.777	10.054
Accumulated Depreciation, Total	-2.215	-2.088	-1.958	-1.826	-1.689
Other Long Term Assets, Total	0.214	0.282	0.428	0.514	0.743
Total Current Liabilities	33.653	33.912	33.69	35.588	37.134
Accounts Payable	7.335	5.762	5.38	7.431	8.442
Accrued Expenses	24.181	24.681	22.767	26.692	27.251
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	2.137	3.469	5.543	1.465	1.441
Total Liabilities	90.075	90.343	116.969	119.218	120.608
Total Long Term Debt	51.246	50.936	77.47	77.015	76.558
Long Term Debt	51.246	50.936	77.47	77.015	76.558
Other Liabilities, Total	5.176	5.495	5.809	6.615	6.916
Total Equity	43.022	57.548	44.988	68.747	45.965
Common Stock	0.005	0.005	0.005	0.005	0.004
Additional Paid-In Capital	812.132	808.454	804.604	800.768	744.338
Retained Earnings (Accumulated Deficit)	-769.107	-750.903	-759.613	-732.018	-698.369
Treasury Stock - Common	-0.008	-0.008	-0.008	-0.008	-0.008
Total Liabilities & Shareholders’ Equity	133.097	147.891	161.957	187.965	166.573
Total Common Shares Outstanding	51.8099	51.7085	51.6593	51.4994	42.8971
Short Term Investments	41.729	48.317	48.08	50.476	29.744

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-147.559	-148.352	-99.254	-122.447	-85.288
Cash From Operating Activities	-128.62	-132.108	-83.742	-99.571	-74.307
Cash From Operating Activities	0.53	0.469	0.582	0.356	0.175
Non-Cash Items	23.716	24.613	19.006	16.449	10.233
Changes in Working Capital	-5.307	-8.838	-4.076	6.071	0.573
Cash From Investing Activities	-50.529	0	0.152	-2.716	-0.709
Capital Expenditures	-0.506	0		-2.716	-0.709
Cash From Financing Activities	52.495	145.863	21.688	2.705	340.494
Financing Cash Flow Items	-0.043	-1.411	-0.62	0	-0.892
Issuance (Retirement) of Stock, Net	52.538	92.274	2.308	2.705	341.386
Net Change in Cash	-126.654	13.755	-61.902	-99.582	265.478
Cash Interest Paid	7.924	2.908	0.997
Other Investing Cash Flow Items, Total	-50.023	0	0.152
Issuance (Retirement) of Debt, Net	0	55	20

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-27.595	-147.559	-113.91	-88.638	-49.192
Cash From Operating Activities	-29.053	-128.62	-97.988	-76.741	-38.184
Cash From Operating Activities	0.132	0.53	0.393	0.254	0.115
Non-Cash Items	4.75	23.716	18.876	13.433	7.071
Cash Interest Paid	2.512	7.924	5.61	3.537	1.716
Changes in Working Capital	-6.34	-5.307	-3.347	-1.79	3.822
Cash From Investing Activities	2.91	-50.529	-30.167	-0.506	0
Capital Expenditures		-0.506	-0.506	-0.506
Cash From Financing Activities	-0.214	52.495	0.145	0.018	0.018
Financing Cash Flow Items	-0.215	-0.043	0	0	0
Issuance (Retirement) of Stock, Net	0.001	52.538	0.145	0.018	0.018
Issuance (Retirement) of Debt, Net		0	0	0	0
Net Change in Cash	-26.357	-126.654	-128.01	-77.229	-38.166
Other Investing Cash Flow Items, Total	2.91	-50.023	-29.661		0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

G1 Therapeutics Company profile

About G1 Therapeutics Inc

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead compound COSELA (trilaciclib), is a therapy designed to help protect hematopoietic stem and progenitor cells (HSPCs) in bone marrow against chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lunger cancer (ES-SCLC). Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor for use in combination with other targeted therapies in multiple oncology indications. The Company's Rintodestrant, is a clinical-stage oral selective estrogen receptor degrader (SERD), for use as a monotherapy and in combination with CDK4/6 inhibitors, initially Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-breast cancer.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, G1 Therapeutics Inc revenues decreased 30% to $31.5M. Net loss increased 49% to $148.4M. Revenues reflect License revenue decrease of 55% to $20.4M. Higher net loss reflects General and Administrative - Balancing increase of 40% to $77.6M (expense), Stock-based Compensation in SGA increase of 45% to $17.3M (expense), Research & Development - Balancing value increase of 8% to $70.6M (expense).

Industry:

Bio Therapeutic Drugs

700 Park Offices Drive
Suite 200
RESEARCH TRIANGLE PARK
NORTH CAROLINA 27709
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024